ALLIANZ-WORLDWIDE-CARE
Allianz Worldwide Care has announced the launch of international healthcare plans for individuals and their families living in China, developed in partnership with sister company, Allianz China General Insurance Company. The healthcare plans, which have been designed specifically for expatriates and local nationals, will initially be available for those living in Shanghai, China’s largest population centre. The creation of the healthcare plans for individuals was a natural evolution for the two Allianz companies, following the successful launch of a range of corporate healthcare plans and the establishment of a dedicated health insurance support centre in the Pudong District of Shanghai in 2012.
Expatriates and local nationals based in Shanghai have a choice of three Core Plans, covering a wide range of in-patient and day-care treatments, along with other benefits such as medical evacuation, diagnostic tests and oncology treatment. The Core Plan can be supplemented by optional plans offering cover for out-patient, maternity, and health and wellbeing treatment. There are also two optional dental plans providing cover for general dental treatment, dental surgery, and orthodontics.
Michael Li, CEO of Allianz China General Insurance Company said, “Our local knowledge and contacts together with Allianz Worldwide Care’s global healthcare expertise have enabled us to provide an outstanding solution to individuals looking for international health insurance. The importance of private health insurance and access to private local and international medical facilities is widely recognised, particularly given China’s overcrowded public hospital system.”
Claude Daboul, Director of Sales, Marketing and Operations at Allianz Worldwide Care added, “Shanghai has a population of approximately 24 million and market insights indicated a growing demand for cover which gives individuals and their families access to private and international medical facilities. Our new healthcare plans, developed in partnership with Allianz China General Insurance Company, provide this. They offer direct settlement for in-patient, out-patient and dental treatment throughout China, and access to Allianz Worldwide Care’s extensive medical network outside of China. The modular design of these plans also means that clients can select the type and level of healthcare cover that’s absolutely right for them.
Daboul continued, “What is equally compelling for clients is that these healthcare plans offer generous levels of cover for pre-existing and newly diagnosed chronic conditions as well as oncology treatment.”
Further information is available at www.allianz.cn/en/products/individualhealthcare
//ends
About Allianz Worldwide Care
Allianz Worldwide Care is the international health and life insurance division of Allianz Worldwide Partners and part of the Allianz Group, which serves more than 75 million customers in over 70 countries worldwide. Allianz Worldwide Care provides insurance solutions for health, life and disability on a global scale. Our focus is on earning and maintaining client loyalty by providing a market leading product range, level of service and support. With a client base that includes many of the Fortune Global 500 companies, Allianz Worldwide Care continues to build a reputation for service excellence in international healthcare. www.allianzworldwidecare.com
About Allianz China General Insurance
Allianz China General Insurance Company Ltd. is headquartered in Guangzhou. Established in 2003 as Allianz’s first P&C branch office in China, it was officially approved by the Chinese Insurance Regulatory Commission in 2010, becoming a registered and fully authorised foreign-owned subsidiary. The company offers multiple insurance services including property, liability, marine, engineering, motor and domestic credit insurance, as well as short-term health insurance and accident insurance to our customers. The company has offices in Shanghai, Shenzhen, Dongguan, Foshan and Jiangmen. As a wholly owned subsidiary of the Allianz Group, the company is able to draw on the resources and expertise of one of the world’s leading insurers and financial services providers. www.allianz.cn/en/products/individualhealthcare
Contact:
Press contacts
Grayling PR
Rachel Sherry
rachel.sherry@grayling.com
+353
87 6622111
or
Nuala Ryan
nuala.ryan@grayling.com
+353
83 4212733
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Yokogawa Collaborates with Shell on Robotics and AI Technology for Plant Maintenance18.6.2025 08:00:00 CEST | Press release
- Streamlining operations and reducing risk in asset integrity management – Yokogawa Electric Corporation (TOKYO: 6841) announces that it has formalized a long-term agreement with Shell Global Solutions International B.V. (“Shell”) to integrate and further develop technologies for utilizing robots and drones in plant monitoring and maintenance. Under the agreement, Yokogawa will add an advanced machine vision tool called Operator Round by Exception (ORE), developed by Shell, into its own OpreX™ Robot Management Core. The enhanced software service will be made available by Yokogawa to customers in the energy, chemicals, and other industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617976629/en/ OpreX Robot Management Core ORE is a digital solution that uses machine vision and AI analytics to enable robots to autonomously perform a number of tasks in the operator round process, such as reading gauges and checking for
Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time18.6.2025 08:00:00 CEST | Press release
Ververica, the original creators of Apache Flink® and a leader in stream processing technology, today announced a new partnership with Aiven, the AI-ready open source cloud data platform. This partnership enables Aiven to provide Ververica’s Unified Streaming Data Platform to their customers, expanding access to enterprise-grade streaming data capabilities for data-driven businesses around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617806011/en/ Ververica Announces Partnership with Aiven - Empowering Leading Enterprises to Create Value from their Data in Real-Time Under the partnership, Aiven customers can now unlock enterprise-grade stream processing with Ververica’s powerful platform — allowing them to make decisions and take actions at speed with data from any source — plus expert support from the original creators of Apache Flink. “This partnership is about removing friction and delivering real business
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 07:00:00 CEST | Press release
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years1 Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis1-3 This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4 Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy o
LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 06:30:00 CEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 03:30:00 CEST | Press release
Maximizing synergies to accelerate the global expansion of biometric info-driven government authentication and security business Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contr
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum